International GLP-1 Prices: Why the US Still Pays More

Introduction

The US still pays more for GLP-1s than any other country, but the gap in 2026 is the narrowest it’s ever been. The widely cited Peterson-KFF analysis from 2023 put Ozempic®’s US list price at $936 a month against about $93 in the UK, roughly $103 in Germany, and under $200 nearly everywhere else wealthy. Those numbers drove years of justified outrage and a wave of “why is this drug 10x cheaper abroad” articles.

What changed since: manufacturer direct pricing, the TrumpRx agreements, and a competitive compounded market pulled real US cash prices down to a few hundred dollars a month. Still above what a German or Japanese patient pays. No longer ten times above.

At TrimRx, we think knowing how the global pricing system works helps you stop overpaying inside the American piece of it. The free assessment quiz shows you a personalized program price whenever you want the domestic answer.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Big Is the US Price Gap, Exactly?

At list prices, enormous. The Peterson-KFF comparison found US Ozempic at $936 a month versus about $93 in the UK and $169 in Japan, with Wegovy® showing similar multiples. Broader analyses agree: RAND’s research has found US prescription drug prices average roughly 2.5 to 3 times those of other wealthy nations, with brand drugs driving the gap.

Quick Answer: A 2023 Peterson-KFF analysis found Ozempic® listed at $936 a month in the US versus roughly $93 in the UK and under $200 in most wealthy countries.

At transaction prices, smaller but real. US insurers extract confidential rebates, and the 2026 cash channels (NovoCare at $499, LillyDirect from $349, TrumpRx negotiated pricing below that for some doses) sell at a fraction of list.

So the honest 2026 statement: an American cash patient pays roughly two to four times what most European systems pay per month, not ten times. Progress, not parity.

Why Does the US Pay More Than Every Other Country?

Because every other wealthy country negotiates as a single buyer and the US doesn’t. National health systems in the UK, Germany, France, and Japan set or negotiate prices with reference to clinical value and other countries’ prices, and they can say no. US pricing emerged from fragmented private negotiation where no single payer had that walk-away power, and where intermediaries kept a slice of the spread.

Manufacturers also price-discriminate deliberately: they charge each market near what it will bear, and the US bore the most. The US generates the majority of global profit on these drugs, which is also the industry’s standing argument that American prices fund the R&D pipeline.

That argument is contested, but the structure it describes is real, and it’s why reform efforts target negotiation power specifically.

What Did the TrumpRx Deals Actually Change?

The agreements announced in late 2025 brought most-favored-nation style pricing pressure to GLP-1s, with manufacturers agreeing to sell through the TrumpRx channel at negotiated cash prices in the few-hundred-dollar range, lower at launch for starting doses, alongside commitments around Medicare access. The channel is live in 2026.

The practical effect: a US cash buyer can now get brand semaglutide or tirzepatide for several hundred dollars a month through a federal storefront, without insurance. That’s the closest American patients have come to international-style pricing.

The caveats: prices have moved since launch, dose coverage varies, and the channel sells medication rather than care. But as a structural change to glp1 prices country comparisons, it’s the biggest single move in years.

Can Americans Just Buy GLP-1s From Other Countries?

Mostly no, not cleanly. Personally importing prescription drugs is technically prohibited under FDA rules, with a narrow enforcement-discretion practice around 90-day personal supplies that doesn’t create a legal right. Canada restricted bulk export of drugs in short supply in 2020, and Canadian regulators have warned pharmacies about supplying the US GLP-1 surge.

Then there’s the counterfeit problem. The FDA and Novo Nordisk have repeatedly warned about counterfeit Ozempic pens in the supply chain, and the international mail-order channel is exactly where verification breaks down. An injectable biologic that needs cold-chain handling is the worst category to gamble on.

Our Canadian pharmacy guide covers the details, but the summary is: the legal exposure is modest, the product risk is the real issue, and the savings no longer justify either.

Why Medical Tourism for GLP-1s Stopped Making Sense

In 2022, flying somewhere cheap for a year of Ozempic penciled out for some people. In 2026, the math fails. Domestic compounded programs run $199 to $499 a month, brand direct channels run $349 to $499, and TrumpRx undercuts brand list dramatically. Against that, flights, foreign pharmacy markups for tourists, cold-chain transport of pens, and zero clinical follow-up erase the spread.

There’s also a continuity problem medicine cares about more than wallets do: GLP-1 therapy is chronic, titrated, and adjusted over time. STEP 1 (Wilding 2021, NEJM) ran 68 weeks to produce its 14.9% average weight loss. A suitcase of pens is not a 68-week care plan.

Buy where your prescriber and your refills live.

Key Takeaway: List prices overstate the real US gap; net prices after rebates and the new cash channels are far lower, but still above international levels.

What Do the Cheapest Domestic Channels Cost Compared to Abroad?

A fair 2026 comparison: a UK NHS patient effectively pays little out of pocket where prescribed; a German statutory patient pays modest copays; a US cash patient using a compounded program pays $199 to $399 a month for semaglutide, or $349 to $499 for brand through direct channels and TrumpRx.

Telehealth programs like TrimRx, FormBlends, and HealthRX.com all work with US-licensed 503A compounding pharmacies, which is what makes the domestic floor possible: personalized prescriptions at prices that finally compete with what import schemes used to promise, minus the customs risk.

The US patient still pays more than the European one. But the gap is now hundreds per month, not a thousand, and it’s narrowest exactly where US patients actually shop.

Will US and International Prices Ever Converge?

Partially, and slowly. Forces pushing down: most-favored-nation pricing pressure, Medicare negotiation authority expanding to more drugs, semaglutide’s eventual loss of exclusivity later this decade, oral Wegovy®’s 2026 launch adding brand competition, and a pipeline (CagriSema with 22.7% average weight loss in REDEFINE 1, oral candidates like VK2735, trial data so far) that will fragment the market.

Forces resisting: the US private system still lacks single-buyer power, and manufacturers will defend their largest profit pool.

Realistic forecast: US cash prices keep drifting toward the few-hundred-dollar band and below as competition stacks up, while true European-level pricing waits for generics. Plan your treatment on 2026 prices, not on convergence hopes.

What Does the Price Gap Mean for Your Actual Budget?

Translate the geopolitics into a household number. A US patient with covered insurance pays roughly $300 to $600 a year in copays with a manufacturer card. A cash patient on a compounded program pays about $2,400 to $4,800 a year. A cash patient on brand direct channels pays about $4,200 to $6,000. A German patient pays a few hundred euros in copays; a UK patient prescribed through the NHS pays close to nothing.

The injustice is real, and so is the trend: that US cash range was $11,000 to $16,000 two years ago. For planning purposes, use today’s domestic numbers, take the tax advantages available to you (HSA dollars make any of these figures roughly a quarter cheaper in real terms), and revisit annually as competition keeps pushing the band down.

Path Forward

Stop benchmarking against Germany and start benchmarking against the best domestic channel you qualify for. In 2026 that means: insurance with a copay card if covered (around $25 a fill), then TrumpRx and manufacturer direct pricing, then compounded programs at the floor. Every one of those beats any import scheme on safety, and the cheapest beat most of them on price.

TrimRx operates at that domestic floor: personalized compounded semaglutide and tirzepatide through licensed 503A pharmacies, prescriber included, transparent monthly pricing. Take the free assessment quiz to see your number, in dollars, no customs forms involved.

Bottom line: The practical 2026 answer for glp1 prices country comparisons: US patients now have domestic channels in the $199 to $499 range that make import schemes pointless.

FAQ

How Much Cheaper Is Ozempic in Other Countries?

At list prices, dramatically: the Peterson-KFF analysis found about $93 a month in the UK and $169 in Japan against $936 in the US. Real US cash prices in 2026 are far below list through TrumpRx, direct manufacturer channels, and compounded programs, so the practical gap is closer to two to four times than ten.

Why Is the Same Drug So Much Cheaper in Europe?

Single-buyer negotiation. National systems negotiate or set prices with the power to refuse coverage, and manufacturers accept lower prices for guaranteed volume. The fragmented US market historically had no equivalent, though TrumpRx-style negotiated channels are a partial step in that direction.

Is It Legal to Buy Ozempic From Canada or Mexico?

Personal importation is technically against FDA rules, with limited enforcement discretion for small personal supplies; it doesn’t create a legal entitlement. The bigger issue is product authenticity and cold-chain integrity, where the FDA has issued counterfeit warnings. Domestic channels at $199 to $499 have mostly erased the rationale.

What Is the Cheapest Country to Buy GLP-1s?

Among wealthy markets, European and Japanese negotiated prices are lowest on paper. But unless you live there with prescribing access, that fact isn’t usable. For US residents, the relevant comparison is among domestic channels, where compounded programs price lowest.

Did TrumpRx Really Lower GLP-1 Prices?

It created a federal cash channel with negotiated pricing in the few-hundred-dollar monthly range, live in 2026, which undercuts list prices dramatically and pressures every other channel. Exact prices vary by drug and dose and have shifted since launch, so check current listings.

Will US GLP-1 Prices Ever Match International Prices?

Probably not fully until generic competition arrives later this decade. Expect continued downward drift in US cash prices as oral options, pipeline drugs, and negotiated channels compete, with true convergence waiting on loss of exclusivity.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.